FdaApplication
NDA 217673
Identifiers
- fda_app_no: NDA217673
Properties
| Property | Value |
|---|---|
| applicant_name | INSMED INC |
| application_type | NDA |
| approval_date | 2025-08-12 |
Revenue by product
BRINSUPRI
| Period | Revenue |
|---|---|
| Q2 2026 | $309.2M |
| Q1 2026 | $207.9M |
| Q4 2025 | $144.6M |
| Q3 2025 | $28.1M |
| Q2 2025 | $0.0M |
| Q1 2025 | $0.0M |
| Q4 2024 | $0.0M |
| Q3 2024 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| BRINSUPRI | BRENSOCATIB | 25MG | TABLET;ORAL |
| BRINSUPRI | BRENSOCATIB | 10MG | TABLET;ORAL |
2 products